Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

8.0%

2 terminated/withdrawn out of 25 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

40%

10 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed trials have results

Key Signals

7 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

10(47.6%)

N/A

5(23.8%)

Phase 2

5(23.8%)

Phase 1

1(4.8%)

21Total

Phase 3(10)

N/A(5)

Phase 2(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT07427576Completed

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

Role: lead

NCT07348302Phase 3Recruiting

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Role: lead

NCT07195929Not ApplicableNot Yet Recruiting

Determination of Blomia Tropicalis Allergen Extract in Prick Test Units

Role: lead

NCT06957496Not ApplicableCompleted

Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization

Role: lead

NCT01842360Phase 2Completed

Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT04898283Phase 3Recruiting

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Role: lead

NCT04435990Phase 3Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Role: lead

NCT04891237Phase 3Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Role: lead

NCT06782217Recruiting

Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy

Role: lead

NCT06790368Recruiting

Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.

Role: lead

NCT05532566Not ApplicableRecruiting

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

Role: lead

NCT05533385Not ApplicableCompleted

Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.

Role: lead

NCT05208060Phase 1Unknown

Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

Role: lead

NCT04874714Phase 3Terminated

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Role: lead

NCT05641272Phase 2Not Yet Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Role: lead

NCT04173013Unknown

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)

Role: collaborator

NCT05400811Phase 3Unknown

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

Role: lead

NCT02527187Phase 2Completed

Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa

Role: lead

NCT02654223Phase 2Completed

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

Role: lead

NCT04363814Phase 3Unknown

Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection

Role: lead